Skip to main content
. Author manuscript; available in PMC: 2022 Mar 29.
Published in final edited form as: Biomed Pharmacother. 2020 Aug 21;130:110596. doi: 10.1016/j.biopha.2020.110596

Fig. 2.

Fig. 2.

Change in New York Heart Association (NYHA) class between baseline and the final follow-up. ARNI angiotensin receptor neprilysin inhibitor; OMT standard optimal medical treatment.